Smartlab Europe

News

PeliBioThermalAdds Service Offerings for Single-Use Products

PeliBioThermal, the global name in temperature controlled packaging solutions, announces new service offerings that support customers who use single use products, such as CoolPall™ Flex single use bulk shippers and CoolGuard™ Advance single use parcel shippers. The company now...

Vetter Once Again Wins Axia Best Managed Companies Award

For the second time in a row, Vetter, a global leading contract development and manufacturing organization (CDMO), has won the Axia Best Managed Companies Award. The pharmaceutical service provider was again honored for its clear vision, innovative approaches, sustainable...

Moderna Reports Positive COVID-19 Vaccine Results in Adolescents

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination....

CanSino Biologics Gets OGYEI GMP Certificate for COVID Vax

CanSino Biologics Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector, trade name Convidecia), has been granted a Good Manufacturing Practice certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021...

ANVISA Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome

Sorrento Therapeutics, Inc. announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC™, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering...

Scitara Raises $5 Million to Accelerate Digital Transformation of Scientific Laboratories

Scitara Corporation, a global provider of laboratory-specific, cloud-based software solutions for the biopharmaceutical and industrial markets, announced the closing of $5 million in a Series A round. The investment was led by Northpond Ventures, with participation from existing investor...

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

Takeda Pharmaceutical Company Limited ("Takeda") announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »